Literature DB >> 15628736

Factors influencing the rate of fibrosis progression in chronic hepatitis C.

Conrado M Fernández-Rodriguez1, Maria Luisa Gutiérrez, Pilar López Serrano, José L Lledó, Cecilio Santander, Teresa Pérez Fernández, Esperanza Tomás, Guillermo Cacho, Manuel Nevado, Maria Luisa Casas.   

Abstract

Alcohol consumption, age at infection, and male gender have been identified as risk factors for faster fibrosis progression in patients with chronic hepatitis C (CHC). Yet the influence of liver steatosis, light to moderate alcohol consumption, or iron overload on this progression remains controversial. To analyze the effect of individual risk factors and their interaction on fibrosis progression in a group of patients with CHC and a definite date of infection, we studied 133 consecutive untreated patients. Covariates included were age, body mass index (BMI), gender, age at infection, alcohol intake, serum lipids, glycemia, serum ALT, AST, GGT, iron, and ferritin, grade and stage (METAVIR and Scheuer), and hepatic stainable iron (Perl's stain). The rate of fibrosis progression was inferred from the METAVIR score. By logistic regression analysis, hepatic steatosis (odds ratio [OR], 3.035; 95% confidence interval [CI], 1.16-7.93), serum ferritin levels higher than 290 ng/ml (OR, 5.5; 1.6-18.65), and light to moderate ethanol intake (1-50 g/day) (OR, 5.22; 1.5-17.67) were independently associated with faster fibrosis progression. There was no effect of interaction between these variables on the rate of fibrosis progression. Liver steatosis, serum ferritin levels, and light to moderate alcohol intake are associated with faster fibrosis progression in chronic hepatitis C. Combination of these factors did not further accelerate this progression. The impact of modification of these factors on progression should be tested in longitudinal studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15628736     DOI: 10.1007/s10620-004-9603-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Venesection therapy of insulin resistance-associated hepatic iron overload.

Authors:  A Guillygomarc'h; M H Mendler; R Moirand; F Lainé; V Quentin; V David; P Brissot; Y Deugnier
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Alcohol use and hepatitis C.

Authors:  Marion G Peters; Norah A Terrault
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C.

Authors:  D Thorburn; G Curry; R Spooner; E Spence; K Oien; D Halls; R Fox; E A B McCruden; R N M MacSween; P R Mills
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

4.  Oxidative stress in chronic hepatitis C: not just a feature of late stage disease.

Authors:  Sanjiv K Jain; Philip W Pemberton; Alexander Smith; Raymond F T McMahon; Peter C Burrows; Ali Aboutwerat; Thomas W Warnes
Journal:  J Hepatol       Date:  2002-06       Impact factor: 25.083

5.  Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels.

Authors:  C Renou; P Halfon; S Pol; P Cacoub; E Jouve; J P Bronowicki; J P Arpurt; H Rifflet; M Picon; X Causse; V Canva; J Denis; A Tran; M Bourliére; D Ouzan; A Pariente; S Dantin; L Alric; V Cartier; M Reville; S Caillat-Zucman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection.

Authors:  M Wright; R Goldin; S Hellier; S Knapp; A Frodsham; B Hennig; A Hill; R Apple; S Cheng; H Thomas; M Thursz
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

7.  Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C.

Authors:  Victor I Machicao; Hugo Bonatti; Murli Krishna; Bashar A Aqel; Frank J Lukens; Justin H Nguyen; Barry G Rosser; Raj Satyanarayana; Hani P Grewal; Winston R Hewitt; Denise M Harnois; Julia E Crook; Jeffery L Steers; Rolland C Dickson
Journal:  Transplantation       Date:  2004-01-15       Impact factor: 4.939

8.  Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C.

Authors:  T Asselah; N Boyer; M-C Guimont; D Cazals-Hatem; F Tubach; K Nahon; H Daïkha; D Vidaud; M Martinot; M Vidaud; C Degott; D Valla; P Marcellin
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

9.  Progression of fibrosis in chronic hepatitis C.

Authors:  Marc G Ghany; David E Kleiner; Harvey Alter; Edward Doo; Farooq Khokar; Kittichai Promrat; David Herion; Yoon Park; T Jake Liang; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

10.  Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

Authors:  L Castéra; C Hézode; F Roudot-Thoraval; A Bastie; E-S Zafrani; J-M Pawlotsky; D Dhumeaux
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

View more
  1 in total

1.  Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection.

Authors:  Mark Thursz
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.